Clinical Trial Update: Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update concerns a Phase 1/2 study evaluating the combination of vorinostat and gefitinib in relapsed or refractory advanced non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Non-Small-Cell Lung Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN